reviewed april 2026|next review october 2026|88 physicians psi has verified|150357 published studies
Teixobactin
Teixobactin is a cyclic depsipeptide antibiotic discovered in 2015 using the iChip method to cultivate previously unculturable soil bacteria, with a dual lipid II/lipid III targeting mechanism that kills gram-positive bacteria including MRSA without detectable resistance development.
Evidence landscape: 150357 published studies
Published studies span antibiotic discovery, structural biology, and synthetic chemistry. Strong animal study data with active analog development.
- 40 Human
- 119 Animal
- 41 Reviews
- 150157 Other research
Not FDA-approved. Not in clinical trials. Chemical synthesis challenges have slowed development. The compound was discovered in 2015 and remains in animal development.
Not available for clinical use. Chemical synthesis of teixobactin is technically challenging due to the cyclic depsipeptide structure. Synthetic analogs with simplified structures are being developed.
Teixobactin targets lipid II and lipid III, essential precursors for bacterial cell wall biosynthesis. By binding lipid substrates rather than proteins, resistance development is extremely unlikely because modifying these lipid targets is lethal to bacteria. The iChip discovery method opened access to previously unculturable soil bacteria as an antibiotic source.
PSI Assessment
The antibiotic resistance crisis has made every genuinely new antibiotic mechanism significant. Teixobactin, discovered in 2015 from a soil bacterium that could not previously be grown in the laboratory, kills MRSA and drug-resistant tuberculosis through a mechanism that makes resistance development extremely unlikely. It binds lipid II and lipid III simultaneously, two essential cell wall building blocks that bacteria cannot modify without killing themselves. No detectable resistance has emerged in laboratory selection experiments. The discovery method (the iChip, which cultivates previously unculturable bacteria) is as significant as the compound itself. The limitation: chemical synthesis is difficult, and teixobactin has not yet entered human testing.
Discovered from unculturable soil bacteria via the iChip. Kills MRSA and TB with no detectable resistance. Dual lipid II/III target. Synthesis challenges have delayed clinical development.
The mechanism targets two essential lipid precursors in bacterial cell wall biosynthesis simultaneously. Teixobactin binds lipid II (a precursor for peptidoglycan, the main structural component of bacterial cell walls) and lipid III (a precursor for wall teichoic acid). By targeting these conserved lipid substrates rather than protein targets, the compound avoids the most common resistance mechanisms. Bacteria would need to fundamentally alter their cell wall biosynthesis to develop resistance, a change that is typically lethal. The iChip technology grows previously unculturable bacteria in their natural soil environment, providing access to novel chemistry.
What the evidence supports
Teixobactin kills gram-positive bacteria including MRSA and Mycobacterium tuberculosis in laboratory and animal infection models. The dual lipid II/lipid III targeting mechanism is structurally characterized and explains the resistance-resistant profile. No detectable resistance emerged in laboratory resistance selection experiments. The iChip discovery method validated a new approach to antibiotic discovery from previously unculturable soil bacteria (Eleftheria terrae). In vivo efficacy is confirmed in murine infection models.
What is not yet established
Whether teixobactin or its synthetic analogs can be manufactured at clinical scale. Human pharmacokinetics, safety, and clinical efficacy (controlled human studies have not been conducted). Activity against gram-negative bacteria is limited. Whether synthetic analogs retain the full resistance-resistant profile of the natural compound. The timeline to first-in-human studies remains uncertain.
Research Evidence
The findings below cover the discovery and resistance-resistant mechanism, the animal model efficacy data, and the synthetic analog development efforts.
Evidence by condition
Evidence dimensions across antibiotic resistance, MRSA, tuberculosis, and drug discovery research. All data is from animal studies. Controlled human studies have not been conducted.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Antibiotic Resistance | ||||
| MRSA | ||||
| Tuberculosis | ||||
| Drug Discovery Platform |
Teixobactin was discovered from Eleftheria terrae using the iChip cultivation method. It kills gram-positive bacteria including MRSA and M. tuberculosis with no detectable resistance development in serial passage experiments.
The 2015 discovery was published in Nature and received broad scientific attention. The dual lipid target mechanism explains the resistance-resistant profile: modifying lipid II or lipid III is lethal to bacteria, so resistance mutations are self-defeating.
In vivo efficacy was demonstrated in murine MRSA infection models, with teixobactin showing protective activity at doses comparable to vancomycin.
The animal model data validates the transition from in vitro to in vivo activity, an important step that many antimicrobial peptides fail. The murine model results support the therapeutic concept.
Synthetic analogs with simplified structures that maintain antimicrobial activity have been developed, addressing the synthesis challenge that has slowed clinical development of the natural compound.
The analog development is the critical path to clinical testing. Whether simplified analogs retain the full resistance-resistant profile of the natural compound is being evaluated.
40 Human|119 Animal|41 Reviews
View all 150357 indexed studiesHow Teixobactin Works
Teixobactin is a cyclic depsipeptide antibiotic produced by Eleftheria terrae. It simultaneously binds lipid II and lipid III, essential precursors for bacterial cell wall biosynthesis, making resistance development extremely unlikely.
Teixobactin attacks bacteria by grabbing onto two essential building blocks (lipid II and lipid III) that bacteria need to construct their cell walls. Because these building blocks are lipid molecules that bacteria cannot easily modify without killing themselves, resistance development is extremely unlikely.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Binds lipid II and lipid III in bacterial cell walls. Produced by Eleftheria terrae via iChip technology.
What is Teixobactin being studied for?
Researchers are studying Teixobactin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Teixobactin overall. This means a compound can have human studies for one condition but only animal data for another.
Antibiotic Resistance
·Animal StudiesNo detectable resistance emerged in laboratory serial passage experiments, the standard method for assessing resistance development potential. The dual lipid target mechanism provides a structural explanation for this resistance-resistant profile.
Limitations: All resistance data is from laboratory studies. Whether the resistance-resistant profile holds in clinical settings with complex bacterial populations is untested. Activity is limited to gram-positive bacteria.
MRSA
·Animal StudiesKills methicillin-resistant Staphylococcus aureus (MRSA) in laboratory and animal infection models (animal research). In vivo efficacy in murine MRSA models is comparable to vancomycin.
Limitations: Controlled human data has not been published. Chemical synthesis challenges have prevented clinical development. Whether teixobactin or its analogs will be tested in humans for MRSA treatment is uncertain.
Tuberculosis
·PreclinicalActivity against Mycobacterium tuberculosis demonstrated in laboratory studies. The dual lipid target mechanism is relevant to mycobacterial cell wall biosynthesis.
Limitations: TB activity is demonstrated in vitro only. No animal TB model data. The path from in vitro mycobacterial killing to TB drug development is long and complex.
Drug Discovery Platform
·Animal StudiesThe iChip method that enabled teixobactin's discovery validated a new approach to antibiotic discovery from previously unculturable soil bacteria. This platform may yield additional novel antibiotics.
Limitations: The platform is a discovery tool, not a therapeutic. Whether the iChip approach will produce additional clinically viable antibiotics is being explored.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical trials. Chemical synthesis challenges have prevented human testing. The compound remains in animal development.
Availability: Not available for clinical use. Research material only. Synthetic analogs are being developed to address manufacturing challenges.
Class context: No human safety data exists. Animal studies show acceptable tolerability in murine infection models. The safety profile of synthetic analogs may differ from the natural compound.
No human safety data exists for teixobactin. Animal model tolerability appears acceptable. The primary barrier to clinical development is chemical synthesis, not safety concerns.
Questions and Comparisons
Questions the evidence raises for a Teixobactin discussion.
Comparison and Related Research
Teixobactin is compared with other approaches to antibiotic-resistant infections.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Landmark discovery of teixobactin using the iChip platform for culturing previously unculturable soil bacteria. The compound killed Gram-positive pathogens including MRSA and Mycobacterium tuberculosis with no detectable resistance development. The dual-target mechanism, binding both lipid II and lipid III, made resistance emergence exceptionally difficult to achieve in laboratory settings.Ling LL et al., 2015 in Nature. View on PubMed
- 2.Mechanistic study confirming that teixobactin binds two essential cell wall precursors, lipid II (peptidoglycan biosynthesis) and lipid III (wall teichoic acid biosynthesis). This dual-target mechanism explains both the broad Gram-positive spectrum and the resistance-proof profile, since mutations in either target alone cannot confer resistance.Homma T et al., 2016 in Antimicrob Agents Chemother. View on PubMed
- 3.First successful total synthesis of simplified teixobactin analogs with retained antimicrobial activity. Replacing the challenging enduracididine residue with commercially available amino acids yielded compounds active against MRSA and VRE, opening the path toward scalable production and structure-activity optimization.Parmar A et al., 2016 in Chem Commun. View on PubMed
- 4.Advanced mechanistic study using solid-state NMR and molecular dynamics to reveal that teixobactin forms supramolecular fibrils on the bacterial surface after binding lipid II. These fibrils create physical disruption of the cell membrane in addition to blocking cell wall synthesis, explaining the rapid bactericidal activity observed in earlier studies.Shukla R et al., 2020 in Nat Commun. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.